Virbac S.A. stock (FR0000031577): Animal health leader navigates sector dynamics

Virbac S.A. maintains its position in the animal health sector with a portfolio centered on therapeutics for companion animals. The company reported steady performance in its core segments during the fiscal year ended December 31, 2024, as detailed in its annual report published March 2025. This update underscores ongoing demand for parasitology and dermatology solutions.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Virbac S.A.: core business model

Virbac S.A. develops, manufactures, and distributes pharmaceuticals and vaccines for companion and food-producing animals. Founded in 1968 and headquartered in Carros, France, the company operates in over 100 countries with a strong emphasis on research and development. Its business model revolves around innovative solutions for veterinarians, pet owners, and farmers, generating revenue primarily from product sales through distribution networks.

The companion animal division, which includes dogs, cats, and horses, accounts for the majority of sales. Key products feature treatments for fleas, ticks, ear mites, and skin conditions. Virbac invests approximately 10% of revenue in R&D annually, as noted in its 2024 annual report published March 2025, supporting a pipeline of new formulations and delivery systems.

Main revenue and product drivers for Virbac S.A.

Revenue is driven by flagship brands like Effitix for parasite control and EpiOtic for ear care. In 2024, companion animal products represented about 70% of total sales, with Europe contributing 45% and North America 25%, according to the fiscal year results disclosed in March 2025. Growth in premium pet care segments bolsters margins amid rising pet ownership globally.

Food animal products, including vaccines and antibiotics for livestock, provide diversification. Recent expansions in aquaculture solutions target sustainable farming practices. The company's focus on over-the-counter ranges expands accessibility in emerging markets.

Industry trends and competitive position

The global animal health market, valued at $50 billion in 2024 per Statista as of January 2025, grows at 6-7% annually, fueled by pet humanization and preventive care. Virbac competes with giants like Zoetis and Merck Animal Health but differentiates through specialized companion animal focus and agile R&D.

Regulatory approvals for novel biologics and digital health tools position Virbac favorably. Its US exposure via Nasdaq-traded shares appeals to American investors seeking international diversification in a resilient sector less correlated with broader equities.

Why Virbac S.A. matters for US investors

Virbac's products reach US veterinarians through partnerships, tapping into the $10 billion domestic pet med market. With shares listed on Euronext but accessible via US brokers, it offers exposure to Europe's stringent pharma standards and Asia growth. Steady dividends and R&D pipeline provide stability amid US market volatility.

Main revenue and product drivers for Virbac S.A.

Geographic expansion drives revenue, with Asia-Pacific sales up 12% in 2024 per annual results. Key drivers include dental hygiene lines like C.E.T. and pain management solutions, increasingly relevant as US pet spending hits record highs.

Conclusion

Virbac S.A. sustains growth through innovation in companion animal health, with solid fundamentals supporting its market role. Investors monitor R&D outputs and regional expansions for future performance. The company's diversified portfolio and global footprint offer balanced exposure in the animal health space.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.